1. Allegrini, P.R., Weidensteiner, C., and McSheehy, P.M. (2006). Direct comparison of macromolecular contrast agent Vistarem with Dotarem for detecting drug effects on tumor vasculature by DCE MRI. Proc Intl Soc Mag Reson Med 14, 2907.
2. Allhenn, D., Shetab Boushehri, M.A., and Lamprecht, A. (2012). Drug delivery strategies for the treatment of malignant gliomas. Int J Pharmaceut 436, 299–310.
3. Barboriak, D.P., MacFall, J.R., and Padua, A.O. (2004). Standardized software for calculation of K trans and Vp from dynamic T1-weighted MR images. In Proceedings of the International Society for Magnetic Resonance in Medicine Workshop on MR in Drug Development: From Discovery to Clinical Therapeutic Trials, McLean Va, USA. 4.
4. Bayer Schering Pharma AG. (2008). MAGNEVIST® (Gadopentetic Acid Dimeglumine Salt Injection). Germany.
5. Blasiak, B., Tomanek, B., Abulrob, A., Iqbal, U., Stanimirovic, D., Albaghdadi, H., Foniok, T., Lun, X., Forsyth, P., and Sutherland, G.R. (2010). Detection of T2 changes in an early mouse brain tumor. Magn Reson Imaging 28, 784–789.